A

AIgnostics

Health Tech & Medtech · Berlin, Germany · Founded 2018

AIgnostics is an artificial intelligence company focused on transforming drug development and diagnostics through computational pathology. The company spun out of Charité – Universitätsmedizin Berlin, a prominent European university hospital, in 2020, based on research that began in 2018. Its founders include CEO Viktor Matyas, CTO Dr. Maximilian Alber, Lead Medical Advisor Professor Frederick Klauschen, and Lead Technical Advisor Professor Klaus-Robert Müller. Matyas has a background in consulting and investment with firms like McKinsey & Company and holds an MBA from INSEAD. The founding team combines expertise in medicine, machine learning, and business. AIgnostics' core business involves developing AI-powered solutions that analyze complex, multimodal biomedical data, primarily for biopharmaceutical companies. Its services support various stages of the pharmaceutical pipeline, including novel target identification, translational research, clinical trials, and the development of companion diagnostics (CDx). The company's business model is centered on collaborations and providing custom services for complex image and data analysis. A key offering is its patented "Explainable AI" technology, which aims to overcome the "black-box" issue in AI by making diagnostic results verifiable through heatmaps and image overlays. In 2024, AIgnostics announced a strategic multi-year collaboration with Bayer to co-develop a novel target identification platform and computational pathology algorithms for precision oncology. The company also works with the Mayo Clinic on developing pathology foundation models. The company has developed foundation models for pathology, such as 'RudolfV' and 'Atlas 2', trained on extensive image datasets. These models are designed to be computationally efficient and to assist in biomarker, cell, and tissue image analysis. AIgnostics provides its clients with access to its technology and proprietary multimodal patient data to accelerate drug research and development. Headquartered in Berlin, Germany, with operations in New York, the company has grown to over 120 employees. AIgnostics has successfully raised over $55 million in funding, including a $34 million Series B round in October 2024. This round was led by ATHOS, with participation from Mayo Clinic, HTGF, and existing investors like Wellington Partners and Boehringer Ingelheim Venture Fund. Keywords: computational pathology, precision medicine, AI diagnostics, drug development, digital pathology, machine learning, biopharma services, biomarker discovery, companion diagnostics, oncology, translational research, multimodal data analysis, target identification, clinical trials, Explainable AI, foundation models, AI pathology, tumor microenvironment, cancer research, Charité spin-off